Industry Overview - The global GLP-1 receptor agonist market is expanding rapidly, with sales expected to exceed $50 billion in 2024, and the global transaction scale in the first quarter of 2025 reaching $13.024 billion, nearly matching the total for the previous year, indicating a significant increase in the weight loss drug market [1] Company Focus - Silverno Pharmaceuticals-B (02591), focused on GLP-1 drug development, recently saw its IPO surge over 270%, achieving a market capitalization of over HKD 32.4 billion, reflecting strong market interest in the GLP-1 sector and endocrine disease treatment [2] - Another notable player, PegBio Pharmaceuticals-B (02565), has also experienced a stock price increase, with a current market capitalization of HKD 9.3 billion, indicating substantial room for growth compared to Silverno Pharmaceuticals-B [2] - PegBio Pharmaceuticals specializes in innovative therapies for chronic diseases and has developed a proprietary high-efficiency target screening and molecular modification platform (HECTOR), which includes a drug molecule design platform featuring PEG technology to enhance drug stability and reduce research costs [2] Product Pipeline - PegBio Pharmaceuticals has developed a core product and five candidate drugs targeting common chronic and metabolic diseases such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease [3] - The core product, Weipinaide, is highlighted as a significant innovation in PegBio's pipeline, supported by national initiatives for major new drug creation [5] Market Positioning - Weipinaide is recognized as a first-line treatment for type 2 diabetes (T2DM) due to its multiple benefits, including rapid onset of action and sustained efficacy over long-term treatment, making it suitable for lifelong management of diabetes [6] - Clinical results show that Weipinaide significantly reduces HbA1c levels within four weeks and maintains efficacy without rebound effects over 52 weeks, aligning with the treatment needs of diabetes patients [6] - Compared to competitors, Weipinaide offers multiple clinical benefits, including weight loss for high BMI patients, comprehensive heart and kidney protection, and improved beta-cell function and insulin sensitivity [7] Strategic Market Insights - China, as the second-largest pharmaceutical market, is projected to have 164 million diabetes patients and 200 to 250 million overweight individuals by 2030, making it a key strategic area for pharmaceutical companies [8] - PegBio Pharmaceuticals is positioned to reshape the domestic T2DM treatment market through its innovative capabilities and the core product Weipinaide, unlocking its intrinsic value as the market potential continues to grow [8]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Core Viewpoint - The company, Silvernote Pharmaceuticals-B (02591), has successfully completed its global offering, raising approximately HKD 635 million through the issuance of 36.56 million shares at a final price of HKD 18.68 per share [1] Group 1: Offering Details - The global offering consisted of 36.56 million shares, with 10% allocated for the Hong Kong public offering and 90% for international offering [1] - The Hong Kong public offering was oversubscribed by 5,341.66 times, while the international offering was oversubscribed by 10.67 times [1] Group 2: Trading Information - The shares are expected to commence trading on the Hong Kong Stock Exchange on August 15, 2025, at 9:00 AM [1]

Core Viewpoint - Silver诺医药-B (02591) has successfully completed its global offering, raising approximately HKD 635 million through the issuance of 36.56 million shares at a final price of HKD 18.68 per share [1] Summary by Category Offering Details - The global offering consisted of 36.56 million shares, with 10% allocated for public offering in Hong Kong and 90% for international offering [1] - The final offer price was set at HKD 18.68 per share, resulting in net proceeds of approximately HKD 635 million from the global offering [1] Subscription Demand - The Hong Kong public offering was oversubscribed by 5,341.66 times, indicating strong demand from local investors [1] - The international offering saw a subscription rate of 10.67 times, reflecting significant interest from international investors [1] Trading Information - The H-shares are expected to commence trading on the Hong Kong Stock Exchange on August 15, 2025, at 9:00 AM [1]

格隆汇8月14日丨银诺医药-B(02591.HK)公告，公司全球发售36,556,400股H股，发售价每股H股18.68港 元，净所得款项6.3亿港元。香港公开发售股份数目占全球发售股份数目10%，获认购5,341.66倍；国际 发售股份数目占全球发售股份90%，获认购10.67倍。假设全球发售于2025年8月15日(星期五)上午八时 正(香港时间)或前成为无条件，预期H股将于2025年8月15日(星期五)上午九时正(香港时间)开始在联交 所买卖。H股将以每手200股H股进行买卖，H股的股份代号将为2591。 ...

除本公告另有界定者外，本公告所用詞彙與廣州銀諾醫藥集團股份有限公司（「本公司」）刊發日 期為2025年8月7日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅作參考用途，並不構成任何人士收購、購買或認購本公司任何證券的要約或誘使作出 要約的邀請。本公告並非招股章程。潛在投資者於決定是否投資於發售股份前應閱覽招股章 程，以獲得有關本公司及下文所述全球發售的詳細資料。任何有關發售股份的投資決定應僅依 賴招股章程中所提供的資料而作出。 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發及派發。本公告不構成或組成在美國或任何其他司法管轄區任何要約或招攬購買或認購任 何證券的一部分。發售股份不曾亦不會根據1933年美國證券法（經修訂）（「美國證券法」）或美 國任何州或其他司法管轄區的證券法進行登記。發售股份不得於 ...

| | | 十档 | 成交明细 | | --- | --- | --- | --- | | | | 70.450 | - -(- -) | | | | 70.400 | - -(- -) | | | | 70.350 | - -(- -) | | | | 70.300 | - -(- -) | | | | 70.250 | - - - - - - ) | | | | 70.200 | 800(3家) | | | | 70.150 | 1600(5家) | | | | 70.100 | 3200(9家) | | 18.680 | | 70.050 | 2000(4家) | | | | 70.000 | 3400(4家) | | | | 69.950 | 200(1家) | | | | 69.900 | 600(2家) | | | | 69.850 | 800(3家) | | | | 69.800 | 200(1家) | | | | 69.750 | 2000(3家) | | | | 69.700 | - -(- -) | | | | 69.650 | - | | | | 69.600 | | | -33.840 ...

- -(- -) 16:15 17:30 18:00 18:30 1分 5分 分时 日K 卖盘十档 买盘十档 25.60% 74.40% 立即卖出 立即买入 • 行情来源: 利弗莫尔证券 | | | 十档 | 成交明细 | | --- | --- | --- | --- | | | | 70.450 | - | | | | 70.400 | - -(- -) | | | | 70.350 | - - (- -) | | | | 70.300 | - | | | | 70.250 | - -(- -) | | | | 70.200 | 800(3家) | | | | 70.150 | 1600(5家) | | | | 70.100 | 3200(9家) | | | | 70.050 | | | 18.680 | | | 2000(4家) | | | | 70.000 | 3400(4家) | | | | 69.950 | 200(1家) | | | | 69.900 | 600(2家) | | | | 69.850 | 800(3家) | | | | 69.800 | 200(1家) | | | | 69.75 ...

本文源自：智通财经网 银诺医药-B(02591)将于8月15日(周五)在香港挂牌。截至发稿，暗盘交易显示报价68.2港元，较招股价 18.68港元上涨265.10%，每手200股，不计手续费，每手赚9904港元。 ...

银诺医药-B(02591)将于8月15日(周五)在香港挂牌。截至发稿，利弗莫尔证券暗盘交易显示报价68.2港元，较招股价18.68港元上涨265.10%，每手200股，不 计手续费，每手赚9904港元。 | 16:16 | | | ·Il 4G 73 | | --- | --- | --- | --- | | { | 银诺医药-B | | | | | HK 02591 暗盘 | | | | 68.200 | 成交 74600股 最高 69.000 | | 今开 37.600 | | +265.10% +49.520 | 换手 0.02% 最低 37.600 | | 总市 286.62亿 | | 16:16 价 68.200 +265.10% 均 64.414 分时量 33200股 | | | | | 68.200 | | | 265.10% 十档 成交 | | | | | 68.950 | | | | | 68.900 | | | | | 68.850 | | | | | 68.800 | | | | | 68.750 | | 18.680 | | | 68.700 | | | | | 280( 68.650 ...